Minerva Biotechnologies is a clinical stage biopharmaceutical company focused on developing immunotherapies for solid tumor cancers and cellular therapies for regenerative medicine. NCT04020575 is Minerva’s first-in-human trial of huMNC2-CAR44, a CAR T that targets the MUC1* growth factor receptor, for the treatment of metastatic breast cancers, 95% of which express a MUC1*. We are now expanding the current clinical trial to include our second CAR-T product that greatly increases persistence. The Company is rapidly accelerating its pipeline that includes next-gen CAR-T products, a straight antibody therapeutic and a small molecule therapeutic which are both for the treatment of cancer metastasis. Our track record of scientific breakthroughs is a testament to our visionary team and our collaborative culture. Join us in changing the world.
Company Details
- Employees
- 18
- Founded
- 1999
- Address
- 40 Bear Hill Rd., Waltham,ma 02451,united States
- Phone
- +1 781-487-0200
- su****@****bio.com
- Industry
- Biotechnology
- Website
- minervabio.com
- HQ
- Waltham, MA
Minerva Biotechnologies Questions
Minerva Biotechnologies's helpline number is +1 781-487-0200
Minerva Biotechnologies's website is minervabio.com
Minerva Biotechnologies's LinkedIn profile is https://www.linkedin.com/company/minerva-biotechnologies
Minerva Biotechnologies has
18 employees.
View email and phone details for 18
employees at Minerva Biotechnologies.
Minerva Biotechnologies's industry is
Biotechnology
Minerva Biotechnologies's top competitors are
Cugene Inc.,
Aleta Biotherapeutics,
Astrazeneca,
Nova Biomedical,
Affyimmune Therapeutics,
Northway Biotech,
Alloy Therapeutics, Inc.,
Orna Therapeutics,
Kymera Therapeutics,
Pillar Biosciences Incorporated.
Minerva Biotechnologies's support email address is support@minervabio.com
Minerva Biotechnologies's categories are Biotechnology
Minerva Biotechnologies's founding year is 1999
